(Q36964693)

17 August 2017

1 reference

title

Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis (English)

1 reference

17 August 2017

3

Stamatios Theocharis

1 reference

17 August 2017

Costas Giaginis

1

1 reference

17 August 2017

Alexandra Margeli

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1561-1572

1 reference

Gene expression profiling in an in vitro model of angiogenesis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

VEGF/VEGFR signalling as a target for inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Clinical implications of angiogenesis in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Activation of the prolactin gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Systemic exposure to rosiglitazone is unaltered by food

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Rosiglitazone inhibits endothelial proliferation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Bifunctional properties of peroxisome proliferator-activated receptor gamma1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-indepen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

PPAR gamma is required for placental, cardiac, and adipose tissue development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Intracellular signalling pathways activated by leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Biological action of leptin as an angiogenic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Leptin regulation of peroxisome proliferator-activated receptor-gamma, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through the downregulation of angiopoietin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Upregulation of VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.10.1561

10.1517/13543784.16.10.1561

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference